Nanoviricides, Inc. financial data

Symbol
NNVC on NYSE
Industry
Pharmaceutical Preparations
Location
1 Controls Drive, Shelton, CT
State of incorporation
NV
Fiscal year end
June 30
Latest financial report
10-Q - Q4 2024 - Feb 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 333 % -70%
Debt-to-equity 11.8 %
Return On Equity -87.9 % -37.4%
Return On Assets -78.7 % -35.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15.6M shares +32.8%
Common Stock, Shares, Outstanding 15.6M shares +32.8%
Entity Public Float 11.4M USD -7.2%
Common Stock, Value, Issued 156 USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 14.6M shares +24.1%
Weighted Average Number of Shares Outstanding, Diluted 14.6M shares +24.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.49M USD -23.3%
General and Administrative Expense 4.04M USD +58.2%
Operating Income (Loss) -9.53M USD +1.82%
Nonoperating Income (Expense) 162K USD -53.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.97M USD -25.3%
Net Income (Loss) Attributable to Parent -9.36M USD -0.09%
Earnings Per Share, Basic -0.72 USD/shares +10%
Earnings Per Share, Diluted -0.72 USD/shares +10%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.96M USD -24.5%
Assets, Current 4.07M USD -23.4%
Property, Plant and Equipment, Net 7.17M USD -7.41%
Intangible Assets, Net (Excluding Goodwill) 321K USD -2.51%
Assets 11.6M USD -13.7%
Employee-related Liabilities, Current 26.3K USD +10.2%
Accrued Liabilities, Current 65.4K USD -63.7%
Liabilities, Current 1.18M USD +24.5%
Liabilities 1.2M USD +26.2%
Retained Earnings (Accumulated Deficit) -145M USD -6.93%
Stockholders' Equity Attributable to Parent 10.4M USD -16.6%
Liabilities and Equity 11.6M USD -13.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.59M USD -121%
Net Cash Provided by (Used in) Financing Activities 1.71M USD
Net Cash Provided by (Used in) Investing Activities -46.8K USD -464%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 15.6M shares +32.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.96M USD -24.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 39.8M USD +6.37%
Deferred Tax Assets, Gross 39.8M USD +6.37%
Depreciation 764K USD +2.19%
Payments to Acquire Property, Plant, and Equipment 46.8K USD +464%
Property, Plant and Equipment, Gross 15M USD +1.28%
Deferred Tax Assets, Operating Loss Carryforwards 29.4M USD +4.98%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 155M USD +4.95%
Amortization of Intangible Assets 2.07K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 13.3K USD